ESTRO 37 Abstract book

S751

ESTRO 37

Results The patient characteristics are listed in the table

had a worse survival (HR 1,65; CI 1,27-2,15, P<0.001). Stage III (HR 2,126; CI 1,156-3,909, P=0.015) and stage IV patients (HR 3,561; CI 1,817-6,977, P<0.001) had a worse survival than stage I-II. Patients who underwent surgery (HR 0,367; CI 0,226-0,595; P<0.001), pulmonary radiotherapy (HR 0,402; CI 0,286- 0,567; P<0.001), or chemotherapy (HR 0,453; CI 0,327-0,628; P<0.001) had lower risk of mortality. The median GHS, PF, RF, EF, CF, and SF scores were 67%, 80%, 33%, 75%, 100%, and 67%, respectively. Patients with higher scores for GHS (HR 0,59; CI 0.45-0.78; P<0.001), PF (HR 0.56; CI 0.43-0.73; P<0.001), EF (HR 0.58; CI 0.44-0.76; P<0.001) and SF (HR 0.65; CI 0.507-0.85; P<0.001) had a lower risk mortality. Multivariate analysis showed that those who had a worse stage had a higher risk of mortality (HR 1,53; CI 1,14- 2,05; P=0.004) while those who underwent surgery (HR 0,37; CI 0,22-0,62; P=0.000), received radiotherapy (HR 0,36; CI 0,25-0,51; P=0.000) or chemotherapy (HR 0,36; CI 0,25-0.52; P=0.000) had a lower risk. Additionally, patients with higher score in the emotional (HR 0,632; CI 0,47-0,85; P=0.002) and rol functioning (HR 0,62; CI 0,45-0,86; P=0.004) associated with lower risk of mortality. We observed that the HRQOL did not impact in survival in elderly patients (>70 years) with good KPS (≥80). However, when elderly patients had KPS < 80, the HRQOL, specifically in RF (HR 0,45; CI 0,25-0,8; P=0.007) and EF (HR 0,42; CI 0,22-0,78; P=0.007) impacted on survival, decreasing the mortality in those patients with higher scores. Conclusion Higher pre-radiotherapy HRQOL scores associates with lower mortality. We were able to find a subset of fragile patients (>70 years old with KPS <80) that may benefit from more radical treatments if they have a good quality of life.Promoting and improving QoL can positively impact in survival and this scoring could be added as prognostic factor to guide our treatment decisions. EP-1376 Prognostic factors for clinical outcome in advanced non-small-cell lung cancer (NSCLC) A. Otero-Romero 1 , I. Navarro-Domenech 1 , A. Román- Jobacho 1 , A. Pérez-Rozos 1 , A. Fernández-Forné 1 , R. Correa-Generoso 1 , R. Ordoñez-Marmolejo 1 , I. García- Ríos 1 , M. García-Anaya 1 , J. Gómez-Millán 1 , J. Medina- Carmona 1 1 Hospital Virgen de la Victoria, Oncología Radioterápica, Málaga, Spain Purpose or Objective To analyse the influence of clinical factors and comorbidity in Overall Survival (OS) and Disease free Survival (DFS) in patients with advanced NSCLC treated with radical radiotherapy and chemotherapy Material and Methods Retrospective analysis of 157 patients with advanced NSCLC treated with radical intention with either concomitant or sequential radiation-chemotherapy from 2005 to 2014 in our department. Age, performance status (ECOG), comorbidity, Haemoglobin at diagnosis, weight loss, histology, Stage, PET scan at diagnosis, PTV volume and timing of Radiotherapy (concomitant versus sequential) were analysed as prognostic factors. Comorbidity was assessed with a simplified score scale (SCS). Kaplan-Meier and multiple regression analysis were performed for statistical analysis. One patient was excluded from analysis due to loss of follow-up. Results 157 patients (138 men, 19 women), median age 64 years (34-83). ECOG0: 49%, ECOG1-2: 51%. SCS 0-7: 31.2%, SCS 8-9: 41.4%, SCS 10-11: 5.7%, SCS>=12: 21.7%. Haemoglobin (Hb) 6-16.9 gr/dl (median 13.4). Weight loss 0-40% (median 2.6%). Stage IIIA: 43.9%, IIIB: 56.1%. PET- scan yes: 28.6%, No PET scan: 41.4%. Squamous 58%, Adenocarcinoma 24.8%, undifferentiated 16.5%. PTV volume from 92-1395 cc(median 580 cc). Concomitant

The median, 1, 2, 3, and 4 year overall survival was 50.5 mo., 88%, 74%, 61%, and 58 % in the S-Grp and 20.0 mo., 72%, 50%, 42%, and 37% in the RT-Grp, (p=.021)

Conclusion The survival after SBRT for patients previously treated with surgery was better than patients previously treated with RT, but the survival in both groups was very good EP-1375 Pre-radiotherapy quality of live assessment predicts survival in lung cancer patients J.M. Nieto-Guerrero Gómez 1 , J. Cacicedo Fernández de Bobadilla 2 , B.D. Delgado León 1 , D. Herrero Rivera 3 , E. Montero Perea 1 , J.M. Praena Fernández 4 , M.J. Ortiz Gordillo 1 , J.L. López Guerra 1 1 Virgen del Rocío University Hospital, Radiation Oncology, Sevilla, Spain 2 Cruces Hospital, Radiation Oncology, Bilbao, Spain 3 Virgen del Rocío University Hospital, Oncology, Sevilla, Spain 4 Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla, Methodology Unit, Sevilla, Spain Purpose or Objective Lung cancer (LC) has a significant impact on patients' health-related quality of life (HRQOL). We investigate the correlations between pre-radiotherapy HRQOL and survival. Material and Methods We conducted a prospective multicentric study with 437 LC patients that were seen in consultation at radiation oncology departments from 2013 to 2016. Quality of live was assessed using the EORTC-QLQ-C30 (v3.0) questionnaire. Global health status (GHS), physical (PF), role (RF), emotional (EF), cognitive (CF) and social functioning (SF) scores were evaluated. Several patient factors, tumor features and treatments were considered for the analysis. Results The median age was 66 years (range 31-88). The TNM classification was as follows: stage I 12 patients, stage II 16 patients, stage III 351 patients and 58 patients with stage IV. Patients with Karnofsky performance status <80